A Florida Board-Approved CE Activity
Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for
the issue, return to this Introduction page and click the "Take the Test" button. The Introduction
page will remain open after you open this issue.
You may need to re-size or close the issue in order
to see the Introduction page.
This CE activity is approved by the Florida Board of Pharmacy and meets the HIV CE requirement for licensure in Florida.
Thirty-three years after the first case of acquired immunodeficiency
syndrome (AIDS) was reported, approximately
35 million persons worldwide are living with
HIV infection, of which 25 million live in sub-Saharan
Africa. In the U.S., an estimated 1.2 million persons are
living with HIV/AIDS. The number of new infections
reported to the Centers for Disease Control and Prevention
(CDC) each year has remained fairly stable since the
mid-1990s, with about 50,000 infections reported per
Drug therapy for HIV infection is complex and
evolving. In developed countries, there have been
substantial advances in antiretroviral (ARV) therapy for
HIV, which have improved survival and the quality of
life for infected individuals. Potent ARV agents now
allow the majority of highly treatment-experienced
persons, who have failed multiple regimens, to achieve
virus suppression and survival benefits similar to those
of treatment-naïve persons.
Between 2004 and 2009, the availability of ARV
therapy reduced disease progression and death by 19%,
allowing HIV to be managed as a chronic disease rather
than a death sentence. Survival rates on ARV therapy
are excellent, but lifespans are not normal compared
to uninfected persons. Life expectancy is shortened by
about 10 years due to the effects of "HIV aging," which
results from persistent viral inflammation. About 50%
of deaths are now due to non-HIV related illnesses, including
cancer, cardiovascular disease, liver disease, and
other diseases associated with aging.
This article will review the modes of HIV transmission,
prevention of HIV including pre- and postexposure
prophylaxis, and infection control precautions.
Key ARV therapy principles are highlighted, and recommendations
for general HIV care by are discussed.
Publication Date: 08/05/2014
Expiration Date: 08/05/2017
CE Credit: 1.5 (0.15 CEU)
Type of Activity: Knowledge-based
This program was developed by The Rx Consultant and published by Continuing Education Network, Inc.
The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and
is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased,
balanced information to health care practitioners.
Programs developed by The Rx Consultant are written by health care providers with expertise in the topic
area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure
that every program presents information that is current, accurate, relevant to "real world" health care
providers, and written in an easy reading, "plain English" style.
The Rx Consultant Editorial Board
The Rx Consultant Editorial Board has nothing to disclose.
This accredited program is targeted to pharmacists and nurses.
Goals & Objectives
At the conclusion of this program, participants will be able to:
- List the modes of HIV transmission and discuss preventive measures for each mode. Counsel patients about reducing their risk of transmission.
- List the antiretroviral (ARV) regimens currently recommended for pre- and post-exposure prophylaxis, and describe their efficacy in preventing HIV transmission.
- State the major provisions of Florida’s Omnibus AIDS Act.
- Identify the preferred ARV drug class combinations for ARV-naïve patients. Discuss the treatment of tuberculosis in HIV-infected patients. Counsel patients about the importance of adherence.
The Rx Consultant is a publication of Continuing Education Network, Inc.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a
provider of continuing pharmacy education.
Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.
ACPE Universal Activity Number: 0428-0000-14-011-H02-P
Exam & Credit Statement Procedures
Upon successful completion of this program and the post test (70%), 1.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and
Editorial and Review Board
Chief Editor and CE Administrator
Terry M. Baker, PharmD
Tracy Farnen, PharmD
James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA
Richard Ron Finley, B.S. Pharm.,R.Ph.
Clinical Pharmacist (volunteer faculty)
University of California, San Francisco (UCSF) Memory and Aging Center
Lecturer (Emeritus) UCSF, Department of Clinical Pharmacy
Health Sciences Clinical Professor, UCSF School of Pharmacy
San Francisco, CA
Ray Dolby Brain Health Center, Sutter Health/CPMC
San Francisco, CA
Consult Pharmacist Aging and Adult Health Services
San Francisco Health Department
San Francisco, CA
Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System
Adjunct Clinical Professor
College of Pharmacy
Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Visiting Associate Professor and Lecturer
Samuel Merritt University
Pamela Mausner, MD
Helen Berlie, Pharm.D. CDE, BCACP
Clinical Assistant Professor, Pharmacy Practice
Wayne State University
Ambulatory Care Specialist - Diabetes
Health Centers Detroit Medical Group
Senior Editorial Advisor
Gerard Hatheway, PharmD, PhD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD
Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners
Meuleman, RN, C, MS
About the Rx Consultant
The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to
educate patients about drugs and manage drug therapy. The reader is responsible for confirming
the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.
Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.
Browser that supports TLS 1.1 + and PDF files.
This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.
Adobe Acrobat Reader is recommended, and is required for some browsers.
Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.
Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)